 Connection
Sara Miller to Antilymphocyte Serum
This is a "connection" page, showing publications Sara Miller has written about Antilymphocyte Serum.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.060 |
|
|
|
-
Wilhelm-Benartzi CS, Miller SE, Bruggraber S, Picton D, Wilson M, Gatley K, Chhabra A, Marcovecchio ML, Hendriks AEJ, Morobé H, Chmura PJ, Bond S, Aschemeier-Fuchs B, Knip M, Tree T, Overbergh L, Pall J, Arnaud O, Haller MJ, Nitsche A, Schulte AM, Mathieu C, Mander A, Dunger D. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open. 2021 12 07; 11(12):e053669.
Score: 0.046
-
Rocha PN, Plumb TJ, Miller SE, Howell DN, Smith SR. Risk factors for BK polyomavirus nephritis in renal allograft recipients. Clin Transplant. 2004 Aug; 18(4):456-62.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|